Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The Seattle Genetics-Pieris pact extended the bispecific IO arms race, layering Anticalin-based costimulation onto Seagen's antibody engineering franchise as a…
Pieris and Seagen amended the 2018 collaboration: Pieris swapped its 50/50 co-development right on program 2 for a US co-promote option plus higher royalties;…
Pieris ended development of cinrebafusp alfa (PRS-343) and pivoted to its respiratory franchise with AstraZeneca, casting doubt on the broader Anticalin IO…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Seattle Genetics and Pieris formed a multi-program immuno-oncology collaboration in February 2018 to develop bispecific Antibody-Anticalin fusion proteins. Seattle Genetics paid $30M upfront with up to $1.2B in success-based milestones across three programs, plus tiered royalties up to low double-digits. Pieris retained the option to co-develop and co-commercialize the second program in the US on a 50/50 basis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pieris Pharmaceuticals, Inc. / Seattle Genetics, Inc. (this deal) | 2018 | $1.2B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2018 deals · Hematology deals